PTAC Pilot and Feasibility Award
Forecasted
Funds early-stage, innovative research to restore or repair CFTR gene function in cystic fibrosis, supporting novel, high-impact approaches toward a cure.
Funder: Cystic Fibrosis Foundation
Due Dates (Anticipated): May 2027 (full application, projected)
Funding Amounts: Up to $50,000/year plus 12% indirect costs, for up to 2 years (max total: $112,000)
Summary: Supports early-stage, innovative research to restore CFTR function or repair/replace the CFTR gene in cystic fibrosis.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
The PTAC Pilot and Feasibility Award, part of the Cystic Fibrosis Foundation's Path to a Cure initiative, provides funding for pilot or early-stage research aimed at developing innovative strategies to restore CFTR protein function or repair/replace the defective CFTR gene in people with cystic fibrosis (CF). The program seeks to accelerate the discovery and development of novel therapies, especially for CFTR mutations not responsive to current modulators, by supporting foundational concepts, novel methods, and high-risk/high-reward approaches that could ultimately lead to a cure.
